Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves IBN.ai

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability.
Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin.
Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system.
The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis.

Multiple sclerosis (“MS”) treatment has traditionally focused on controlling the immune activity that drives new inflammatory lesions and relapses. While this approach has transformed the management of relapsing MS, growing attention is being directed toward another fundamental challenge: protecting the nervous system from the damage that can accumulate over time and contribute to disability progression.

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS, an oral, first-in-class new chemical entity designed to address demyelination through a fundamentally different therapeutic approach. Rather than primarily suppressing or depleting immune cells, Lucid-MS is being developed to protect myelin and inhibit processes that contribute to…